These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 36092368)

  • 1. Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper.
    Yang TY; Braun M; Lembke W; McBlane F; Kamerud J; DeWall S; Tarcsa E; Fang X; Hofer L; Kavita U; Upreti VV; Gupta S; Loo L; Johnson AJ; Chandode RK; Stubenrauch KG; Vinzing M; Xia CQ; Jawa V
    Mol Ther Methods Clin Dev; 2022 Sep; 26():471-494. PubMed ID: 36092368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PK/PD and Bioanalytical Considerations of AAV-Based Gene Therapies: an IQ Consortium Industry Position Paper.
    Kavita U; Sun K; Braun M; Lembke W; Mody H; Kamerud J; Yang TY; Braun IV; Fang X; Gao W; Gupta S; Hofer M; Liao MZ; Loo L; McBlane F; Menochet K; Stubenrauch KG; Upreti VV; Vigil A; Wiethoff CM; Xia CQ; Zhu X; Jawa V; Chemuturi N
    AAPS J; 2023 Jul; 25(5):78. PubMed ID: 37523051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy.
    Gorovits B; Azadeh M; Buchlis G; Fiscella M; Harrison T; Havert M; Janetzki S; Jawa V; Long B; Mahnke YD; McDermott A; Milton M; Nelson R; Vettermann C; Wu B
    AAPS J; 2023 Apr; 25(3):47. PubMed ID: 37101079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia.
    Monahan PE; Négrier C; Tarantino M; Valentino LA; Mingozzi F
    J Clin Med; 2021 Jun; 10(11):. PubMed ID: 34199563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Humoral Response to Adeno-Associated Virus-Based Gene Therapy Modalities Using Total Antibody Assays.
    Gorovits B; Azadeh M; Buchlis G; Harrison T; Havert M; Jawa V; Long B; McNally J; Milton M; Nelson R; O'Dell M; Richards K; Vettermann C; Wu B
    AAPS J; 2021 Sep; 23(6):108. PubMed ID: 34529177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming the Challenges Imposed by Humoral Immunity to AAV Vectors to Achieve Safe and Efficient Gene Transfer in Seropositive Patients.
    Gross DA; Tedesco N; Leborgne C; Ronzitti G
    Front Immunol; 2022; 13():857276. PubMed ID: 35464422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies.
    Di Minno G; Miesbach W; Castaman G; Peyvandi F
    Haematologica; 2024 Mar; ():. PubMed ID: 38450517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral Immune Response to AAV.
    Calcedo R; Wilson JM
    Front Immunol; 2013 Oct; 4():341. PubMed ID: 24151496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune responses to adeno-associated virus vectors.
    Zaiss AK; Muruve DA
    Curr Gene Ther; 2005 Jun; 5(3):323-31. PubMed ID: 15975009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A.
    Long BR; Veron P; Kuranda K; Hardet R; Mitchell N; Hayes GM; Wong WY; Lau K; Li M; Hock MB; Zoog SJ; Vettermann C; Mingozzi F; Schweighardt B
    Mol Ther; 2021 Feb; 29(2):597-610. PubMed ID: 33309883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune responses to AAV vectors: overcoming barriers to successful gene therapy.
    Mingozzi F; High KA
    Blood; 2013 Jul; 122(1):23-36. PubMed ID: 23596044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them.
    Hareendran S; Balakrishnan B; Sen D; Kumar S; Srivastava A; Jayandharan GR
    Rev Med Virol; 2013 Nov; 23(6):399-413. PubMed ID: 24023004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adeno-Associated Viruses (AAV) and Host Immunity - A Race Between the Hare and the Hedgehog.
    Rapti K; Grimm D
    Front Immunol; 2021; 12():753467. PubMed ID: 34777364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions.
    Basner-Tschakarjan E; Mingozzi F
    Front Immunol; 2014; 5():350. PubMed ID: 25101090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommendations for the Development of Cell-Based Anti-Viral Vector Neutralizing Antibody Assays.
    Gorovits B; Fiscella M; Havert M; Koren E; Long B; Milton M; Purushothama S
    AAPS J; 2020 Jan; 22(2):24. PubMed ID: 31907680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral immune responses to AAV gene therapy in the ocular compartment.
    Whitehead M; Osborne A; Yu-Wai-Man P; Martin K
    Biol Rev Camb Philos Soc; 2021 Aug; 96(4):1616-1644. PubMed ID: 33837614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors.
    Basner-Tschakarjan E; Bijjiga E; Martino AT
    Front Immunol; 2014; 5():28. PubMed ID: 24570676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adeno-associated virus (AAV) capsid engineering in liver-directed gene therapy.
    Rodríguez-Márquez E; Meumann N; Büning H
    Expert Opin Biol Ther; 2021 Jun; 21(6):749-766. PubMed ID: 33331201
    [No Abstract]   [Full Text] [Related]  

  • 19. From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy.
    Grimm D; Kay MA
    Curr Gene Ther; 2003 Aug; 3(4):281-304. PubMed ID: 12871018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Response Mechanisms against AAV Vectors in Animal Models.
    Martino AT; Markusic DM
    Mol Ther Methods Clin Dev; 2020 Jun; 17():198-208. PubMed ID: 31970198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.